Generic Zituvio Availability
Last updated on Sep 10, 2026.
Zituvio is a brand name of sitagliptin, approved by the FDA in the following formulation:
| Manufacturer | Approval date | Strengths [RLD] |
|---|---|---|
| ZYDUS LIFESCIENCES | October 18, 2023 |
|
Has a generic version of Zituvio been approved?
Yes, the following Zituvio generics have been approved by the FDA:
Authorized generic versions| Company | NDC Code Number | Formulation |
|---|---|---|
| Zydus Pharmaceuticals (USA) Inc. | 707101899 |
Sitagliptin ORAL TABLET 25 mg |
| Zydus Pharmaceuticals (USA) Inc. | 707101900 |
Sitagliptin ORAL TABLET 50 mg |
| Zydus Pharmaceuticals (USA) Inc. | 707101901 |
Sitagliptin ORAL TABLET 100 mg |
| Zydus Lifesciences Limited | 707711790 |
Sitagliptin ORAL TABLET 25 mg |
| Zydus Lifesciences Limited | 707711791 |
Sitagliptin ORAL TABLET 50 mg |
| Zydus Lifesciences Limited | 707711792 |
Sitagliptin ORAL TABLET 100 mg |
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Zituvio. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Generic Zituvio prices
Pricing information is not currently available. While the medication may be approved, it does not appear to be commercially available at this time. Market launch delays can occur. For the most accurate and up-to-date information, consider contacting the manufacturer.
Patent protection
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development. These patents may include claims related to the drug's formulation, manufacturing process, or other aspects.
| Patent Title | Pharmaceutical compositions of sitagliptin |
|---|---|
| Patent Number | 10,925,871 |
| Issue Date | February 23, 2021 |
| Inventor | Khera Brij & Kannan Muthaiyyan Essakimuthu & Patel Jitendra Rameshchandra & Amin Saurin Mukundbhai |
| Current Assignee | CADILA HEALTHCARE LIMITED |
| Patent Description |
The present invention relates to stable oral pharmaceutical compositions of sitagliptin base and processes for the preparation thereof.
|
| Patent Expiry Dates |
February 25, 2035
Drug Product: Yes |
More about Zituvio (sitagliptin)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: dipeptidyl peptidase 4 inhibitors
- Breastfeeding
- En español
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
Related/similar drugs
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
